Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol NTN4 contributors: mct/npt - updated : 15-04-2008
HGNC name netrin 4
HGNC id 13658
EXPRESSION
Type widely
   expressed in (based on citations)
organ(s)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Olfactory (smell)olfactory bulb   highly
Reproductivefemale systemovary  highly
Urinarybladder   highly
 kidney   highly
Visualeyeretina  highly
tissue
SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
Connectivebone  highly
cell lineage
cell lines
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • a laminin-like domain VI
  • 3.5 laminin EGF repeats
  • a netrin C domain
  • HOMOLOGY
    interspecies homolog to murine Ntn4
    Homologene
    FAMILY
  • netrin family
  • CATEGORY structural protein
    SUBCELLULAR LOCALIZATION extracellular
    intracellular,cytoplasm,organelle,lumen
    text basement membrane
    basic FUNCTION
  • acts as an antiangiogenic factor through binding to neogenin (NEO1) and recruitment of UNC5B
  • promotes neurite elongation from olfactory bulb explants and is important in neural, kidney, and vascular development
  • may improve poststroke functional recovery by enhancing blood vessel proliferation (Hoang 2009)
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
  • basement membrane component (present in the basement membranes of the vasculature, kidney, and ovaries)
  • INTERACTION
    DNA
    RNA
    small molecule
    protein
    cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    constitutional     --over  
    in VEGF-stimulated endothelial cells
    constitutional       gain of function
    in the ischemic core as soon as 1 day after cerebral ischemia, with subsequent downregulation after 1 week (Hoang 2009)
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target could be a promising alternative avenue for therapeutic intervention to anti-VEGF therapies
    ANIMAL & CELL MODELS